EGFR antisense RNA 1 (EGFR-AS1)

EGFR antisense RNA 1 (EGFR-AS1) is a long noncoding RNA (lncRNA) transcribed from the antisense strand of the epidermal growth factor receptor (EGFR) gene locus on chromosome 7p11.2[3]. It functions primarily by binding directly to EGFR mRNA, inhibiting its degradation and thus sustaining EGFR signaling[2][5]. EGFR-AS1 is consistently upregulated in a variety of human cancers, where it acts in an oncogenic manner by promoting cell proliferation, invasion, chemoresistance, and progression through stabilization of EGFR and downstream pathways[2][3][5]. EGFR-AS1 also serves as a competing endogenous RNA (ceRNA), sponging microRNAs and impacting other signaling axes (such as the miR-524-5p/DRAM1 axis in non-small cell lung cancer), further contributing to tumorigenesis[4]. High EGFR-AS1 expression is associated with poor prognosis, larger tumor size, advanced cancer stage, and has been proposed as both a biomarker and a therapeutic target[3][5]. Its functional roles extend beyond cancer into other disease processes, and its targeting raises the potential for modulating response to EGFR-targeted drugs such as tyrosine kinase inhibitors[3][5].

Other names

EGFR-AS1epidermal growth factor receptor antisense RNA 1lncRNA EGFR-AS1

Regulates resistance or sensitivity to tyrosine kinase inhibitors by stabilizing EGFR mRNA and enhancing EGFR signaling[5][3] Modulates response to chemotherapeutic agents (e.g., cisplatin, gemcitabine) via gene expression regulation and cell cycle effects[3]